ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1716

The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.

Jessica Fairley1, Laura Ross1, Elizabeth Paratz2, Penelope McKelvie3, Simin Daneshvar3, Shereen Oon4, Dylan Hansen3, Wendy Stevens1, Andre La Gerche2 and Mandana Nikpour5, 1The University of Melbourne, Melbourne, Victoria, Australia, 2St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, 3St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, 4St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, 5University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Mortality, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

Session Type: Abstract Session

Session Time: 3:00PM-3:15PM

Background/Purpose: Cardiovascular disease is the leading cause of death in systemic lupus erythematosus (SLE).1 Whilst histopathology remains the gold standard for establishing the pathogenesis of cardiac disease, endomyocardial biopsy is invasive and subject to sampling error. We aimed to examine the frequency of cardiovascular disease in SLE compared with the general population, and associations of specific findings with patient outcomes.

Methods: A case-control study was performed using data from the Australian National Coronial Information System, a database of deaths referred for forensic investigation. SLE cases were identified via keyword/ICD-10 code search. Age- and sex-matched controls were selected from victims of motor vehicle accidents. Demographic data and autopsy findings (macroscopic and histopathological) were extracted. Cardiomegaly was defined as heart weight >95th centile for body weight/sex. Odds ratios (OR) were calculated with 95% confidence intervals (CI).

Results: 123 SLE cases and 123 controls were included. Both groups were predominantly female (85%) and of similar age (median SLE 53 (IQR 40-65) years vs. control 54 (41-65) years, p=0.90).After adjusting for age and sex, myocardial fibrosis (OR 3.4, 95%CI 1.8-6.5, p< 0.01), myocardial inflammatory infiltrates (OR 15.5, 95%CI 3.5-68.5, p< 0.01) and pericardial abnormalities (OR 8.9, 95%CI 3.7-21.3, p< 0.01) were significantly more common in SLE (Figure 1). SLE cases were 6.2-times more likely to have cardiomegaly (95% CI 3.2-12.1, p< 0.01). Moderate-to-severe epicardial coronary artery disease (CAD; OR 2.8, 95% CI 1.5-5.2, p< 0.01), myocardial infarction (OR 5.5, 95% CI 1.8-16.7, p< 0.01) and abnormalities of the small intramural coronary vessels (OR 9.6, 95% CI 2.2-42.4, p< 0.01) were more common in SLE after age and sex adjustment. These associations persisted after adjustment for age, sex and moderate to severe CAD (cardiomegaly OR 4.9, 95% CI 2.5-9.7, p< 0.01; myocardial fibrosis OR 3.4, 95%CI 1.8-6.5, p< 0.01; myocyte hypertrophy OR 8.2, 95%CI 2.7-24.8, p< 0.01; small intramural coronary vessel abnormalities OR 9.9, 95%CI 2.2-45.0, p< 0.01). Coronary vasculitis was exclusively identified in 8% of SLE cases. Valvular pathology was more common in SLE (OR 4.9, 95% CI 2.2-10.8, p< 0.01), with vegetations observed in 6% of cases. Cardiovascular death was more common in SLE cases with myocardial fibrosis (OR 2.6, 95% CI 1.1-5.9, p=0.02), moderate-to-severe CAD (OR 4.0, 95% CI 1.8-9.2, p< 0.01) and cardiomegaly (OR 3.6, 95% CI 1.6-7.9, p< 0.01), after adjusting for age and sex (Table 1). Sudden cardiac death was more common in those with cardiomegaly (OR 3.4, 95% CI 1.5-7.5, p< 0.01) and moderate-to-severe CAD (OR 2.5, 95%CI 1.1-5.7, p=0.03), after age and sex adjustment.

Conclusion: SLE is associated with a significant excess of atherosclerotic vascular, inflammatory and fibrotic cardiac lesions. These data highlight the scope of cardiovascular abnormalities occurring in SLE, and their association with cardiovascular causes of death.References1. Taylor T, Anastasiou C, Ja C, et al. Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study. Arthritis Care Res (Hoboken) 2023; 75(1): 61-8.

Supporting image 1Figure 1: Odds of cardiovascular disease in SLE compared to controls using logistic regression, adjusted for age and sex.

Abbreviations: CI (confidence interval), OR (odds ratio), SLE (systemic lupus erythematosus). 1Cardiomegaly defined as heart weight >95th centile for body weight. 2Valvular pathology defined as at least moderate aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation. 3Coronary artery disease defined as moderate to severe when stenosis >50% vessel occlusion, or qualitative description of “moderate”, “severe” or “critical”. 4Small vessel coronary abnormalities defined as thickening, vasculitis or other abnormality within the small intramural coronary arteries.

Supporting image 2Table 1: Logistic regression analysis describing the association between cardiovascular abnormalities and both any cardiovascular death and sudden cardiac death in SLE cases only, adjusted for age and sex.

Abbreviations: CI (confidence interval), OR (odds ratio), SLE (systemic lupus erythematosus). 1Cardiomegaly defined as heart weight >95th centile for body weight. 2Coronary artery disease defined as moderate to severe when stenosis >50% vessel occlusion, or qualitative description of “moderate”, “severe” or “critical”. 3Valvular pathology defined as at least moderate aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation.


Disclosures: J. Fairley: Boehringer-Ingelheim, 6, Pfizer, 12, Support for ACR Registration 2021; L. Ross: None; E. Paratz: Bristol-Myers Squibb(BMS), 6, Pfizer, 12, Conference Sponsorship; P. McKelvie: None; S. Daneshvar: None; S. Oon: None; D. Hansen: None; W. Stevens: Boehringer-Ingelheim, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Merck/MSD, 2; A. La Gerche: None; M. Nikpour: AstraZeneca, 2, 6, Boehringer Ingelheim, 2, 5, 6, GSK, 2, 6, Janssen Pharmaceuticals, 2, 5, 6.

To cite this abstract in AMA style:

Fairley J, Ross L, Paratz E, McKelvie P, Daneshvar S, Oon S, Hansen D, Stevens W, La Gerche A, Nikpour M. The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-frequency-and-impact-of-cardiovascular-disease-in-systemic-lupus-erythematosus-a-nationwide-matched-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-frequency-and-impact-of-cardiovascular-disease-in-systemic-lupus-erythematosus-a-nationwide-matched-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology